https://www.advanzpharma.com/product-risk-materials/deferiprone-uk2025-02-14weekly1.0https://www.advanzpharma.com/product-risk-materials/emtricitabine-tenofovir-united-kingdom2024-07-08weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-romania2024-06-18weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-sweden2024-05-16weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-germany2024-05-15weekly1.0https://www.advanzpharma.com/product-risk-materials/levofloxacin-united-kingdom2023-09-11weekly1.0https://www.advanzpharma.com/product-risk-materials/levothyroxine-uk2023-06-15weekly1.0https://www.advanzpharma.com/product-risk-materials/levothyroxine-ireland2023-01-20weekly1.0https://www.advanzpharma.com/product-risk-materials/ocaliva-canada2022-12-21weekly1.0https://www.advanzpharma.com/product-risk-materials/lenalidomide-uk2022-10-26weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-slovenia-12022-10-19weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-slovenia2022-10-19weekly1.0https://www.advanzpharma.com/product-risk-materials/chloromycetin-ireland2022-09-15weekly1.0https://www.advanzpharma.com/product-risk-materials/methotrexate-ireland2022-02-14weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-united-kingdom2021-12-13weekly1.0https://www.advanzpharma.com/product-risk-materials/digoxin-usa2021-11-19weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-spain2021-09-27weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-greece2021-09-27weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-cyprus2021-09-27weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-austria2021-09-27weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-belguim2021-07-12weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-czech-republic2021-07-12weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-luxemborg2021-07-12weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-norway2021-05-14weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-ireland2021-05-14weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-finland2021-05-14weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-denmark2021-05-14weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant-the-netherlands2021-04-13weekly1.0https://www.advanzpharma.com/product-risk-materials/nicardipine-united-kingdom2021-03-15weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-switzerland2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-kuwait2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-south-africa2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-norway2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-australia2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-france2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-denmark2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-ireland2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole-united-kingdom2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/methotrexate-united-kingdom2021-03-10weekly1.0